Reprogramming the course of cancer

Technology

Our platform technologies are designed to administer cancer fighting tumor suppressor genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Pipeline

We are developing our lead product candidate, Oncoprex™ immunogene therapy, to be administered in combination with targeted therapies and immunotherapies for non-small cell lung cancer. Preclinical research indicates that Oncoprex might also be effective in fighting other types of cancer and we are exploring its use in other cancer types.

Management Team

We are a multidisciplinary team with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.

Learn More

About Us


At Genprex, we are committed to pioneering a new approach to treating cancer, based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

What they’re saying

In the Media


Catch up with our

Latest News


Genprex to Present at the MicroCap Rodeo Investor Conference

Genprex will present in Austin, Texas on Tuesday, October 15 at 9:10 a.m. CDT.

Genprex’s Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support

Additional research is being done in the field that validates non-viral vector delivery as the next evolution in gene therapy.

5 Things to Know about Lung Cancer Treatment

Getting a lung cancer diagnosis can be a paralyzing moment. Genprex outlines five things you should know about lung cancer treatment.

A Deeper Dive into the Nature Research Scientific Report on TUSC2 and Triple-Negative Breast Cancer

Genprex takes a deeper dive into the data of the study to provide analysis and a better understanding of what the study found and what it means for TUSC2.